Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Moore · SciRah

Researcher profile · Semantic Scholar

K. Moore

Share profile

K. Moore — researcher profile on SciRah

h-index: 16
Works: 52
Citations: 1,111

Most-cited papers

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
M. Levi, K. Moore, C. Castillejos, D. Kubitza +6 more
2014Journal of Thrombosis and Haemostasis204 citations Open access
Semantic Scholar
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
Clapton S. Dias, K. Moore, J. Murphy, J. Ariyawansa +3 more
2016American Journal of Nephrology130 citations Open access
Semantic Scholar
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF
I. Girgis, M. Patel, G. Peters, K. Moore +6 more
2014Journal of clinical pharmacology111 citations Open access
Semantic Scholar
Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
M. Weir, V. Ashton, K. Moore, Shubham Shrivastava +2 more
2020American Heart Journal61 citations Open access
Semantic Scholar
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban
K. Moore, A. Plotnikov, An Thyssen, N. Vaccaro +2 more
2011Journal of Cardiovascular Pharmacology61 citations
Semantic Scholar
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
X. Xu, K. Moore, Paul R. Burton, K. Stuyckens +5 more
2012British Journal of Clinical Pharmacology53 citations Open access
Semantic Scholar
Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube
K. Moore, M. A. Krook, Seema Vaidyanathan, Troy C. Sarich +2 more
2014Clinical pharmacology in drug development48 citations Open access
Semantic Scholar
An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
K. Moore, Seema Vaidyanathan, J. Natarajan, J. Ariyawansa +2 more
2014Journal of clinical pharmacology47 citations Open access
Semantic Scholar
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers
J. Levy, K. Moore, M. Neal, D. Schneider +3 more
2018Journal of Thrombosis and Haemostasis41 citations Open access
Semantic Scholar
Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data
O. S. Costa, J. Beyer-Westendorf, V. Ashton, D. Milentijevic +3 more
2020Current Medical Research and Opinion33 citations Open access
Semantic Scholar
Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban.
K. Moore, D. Kröll
2017American Journal of Medicine33 citations Open access
Semantic Scholar
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data
O. S. Costa, J. Beyer-Westendorf, V. Ashton, D. Milentijevic +3 more
2020Journal of Thrombosis and Thrombolysis31 citations
Semantic Scholar
Randomized 5‐Treatment Crossover Study to Assess the Effects of External Heat on Serum Fentanyl Concentrations During Treatment With Transdermal Fentanyl Systems
K. Moore, G. Sathyan, U. Richarz, J. Natarajan +1 more
2012Journal of clinical pharmacology29 citations
Semantic Scholar
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
V. Ashton, Sylvia Kerolus-Georgi, K. Moore
2021Journal of clinical pharmacology25 citations Open access
Semantic Scholar
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
J. Berger, F. Laliberté, A. Kharat, D. Lejeune +4 more
2021Current Medical Research and Opinion23 citations Open access
Semantic Scholar
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis‐mediated conditions
Troy C. Sarich, G. Peters, S. Berkowitz, F. Misselwitz +16 more
2013Annals of the New York Academy of Sciences20 citations
Semantic Scholar
A Cross‐Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies
Li-Ping Zhang, G. Peters, L. Haskell, Purve Patel +2 more
2017Journal of clinical pharmacology16 citations Open access
Semantic Scholar
Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers.
K. Moore, Dominique St-Fleur, N. C. Marricco, J. Ariyawansa +4 more
2010Journal of Opioid Management15 citations
Semantic Scholar
Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI
A. Khorana, J. Barnard, T. Wun, U. Vijapurkar +4 more
2021Blood Advances13 citations Open access
Semantic Scholar
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
V. Ashton, Lana Mudarris, K. Moore
2020American Journal of Cardiovascular Drugs12 citations Open access
Semantic Scholar
Bioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir system.
K. Moore, H. Adams, J. Natarajan, J. Ariyawansa +1 more
2018Journal of Opioid Management11 citations
Semantic Scholar
Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban
K. Moore, Peggy H. Wong, Li-Ping Zhang, Guohua Pan +1 more
2018Current Medical Research and Opinion11 citations Open access
Semantic Scholar
Special Populations: Profiling the Effect of Obesity on Drug Disposition and Pharmacodynamics
K. Moore
2019Drug Discovery and Evaluation: Methods in Clinical Pharmacology10 citations
Semantic Scholar
A Randomized Study of the Effects of Food on the Pharmacokinetics of Once‐Daily Extended‐Release Hydromorphone in Healthy Volunteers
K. Moore, Dominique St-Fleur, Nadia Cardillo Marricco, J. Ariyawansa +4 more
2011Journal of clinical pharmacology10 citations
Semantic Scholar
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States
J. Berger, F. Laliberté, A. Kharat, D. Lejeune +4 more
2022Journal of Thrombosis and Thrombolysis9 citations Open access
Semantic Scholar
Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
K. Moore, William M. Byra, Seema Vaidyanathan, J. Natarajan +3 more
2015British Journal of Clinical Pharmacology7 citations Open access
Semantic Scholar
The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct
K. Moore, O. Grundmann, O. Iwuchukwu, N. Rakhmanina
2022Journal of clinical pharmacology6 citations
Semantic Scholar
Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
J. Berger, F. Laliberté, A. Kharat, D. Lejeune +4 more
2021Advances in Therapy6 citations Open access
Semantic Scholar
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease
A. Volkl, K. Moore, L. Haskell, E. Barnathan
2023American Journal of Cardiovascular Drugs5 citations Open access
Semantic Scholar
Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population
J. Berger, F. Laliberté, A. Kharat, D. Lejeune +4 more
2021Journal of Medical Economics5 citations Open access
Semantic Scholar
Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.
F. Laliberté, V. Ashton, A. Kharat, D. Lejeune +4 more
2021Journal of Comparative Effectiveness Research5 citations Open access
Semantic Scholar
Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
O. S. Costa, J. Beyer-Westendorf, V. Ashton, D. Milentijevic +3 more
2020Clinical and applied thrombosis/hemostasis5 citations Open access
Semantic Scholar
The Use of Rivaroxaban in Patients With Atrial Fibrillation Receiving Hemodialysis-Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
K. Moore
2019Chest3 citations
Semantic Scholar
ORAL ANTICOAGULATION UNDERUSED AND ASPIRIN OVERUSED FOR ATRIAL FIBRILLATION WITH ADVANCED CHRONIC KIDNEY DISEASE STATUS
M. Dorsch, S. Pokorney, M. Birmingham, J. House +10 more
2019Journal of the American College of Cardiology3 citations Open access
Semantic Scholar
Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate
K. Moore, P. Zannikos, B. Solanki, A. Greenspan +2 more
2012Journal of clinical pharmacology2 citations
Semantic Scholar
Characterization of the steady-state pharmacokinetic profile of once-daily hydromorphone ER (OROS hydromorphone) versus IR hydromorphone in healthy volunteers
U. Richarz, Joris J. Vandenbossche, K. Moore
20112 citations Open access
Semantic Scholar
Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease".
M. Weir, V. Ashton, K. Moore, Shubham Shrivastava +2 more
2020American Heart Journal1 citations
Semantic Scholar
Use of Rivaroxaban and Apixaban, Two Non-Vitamin K Antagonist Oral Anticoagulants (NOACs), in Renally Impaired Patients - the limits of our knowledge
K. Moore, Maria Langas
20181 citations Open access
Semantic Scholar
READMISSIONS FOR MAJOR BLEEDING OR FALLS ARE UNCOMMON IN AN UNSELECTED POPULATION OF PATIENTS HOSPITALIZED WITH ATRIAL FIBRILLATION
G. Fermann, Roberta A. James, K. Moore, B. Shah +3 more
20181 citations Open access
Semantic Scholar
tolerability, Pharmacokinetics and Pharmacodynamics of Apixaban, Aspirin and Clopidogrel Following Coadministration in Healthy Subjects : 2-54-2000057
Charles E. Frost, Zhigang Yu, P. Wastall, S. Nepal +2 more
20141 citations
Semantic Scholar
Characterization of the pharmacokinetic profile of single-dose once-daily hydromorphone ER (OROS hydromorphone) versus IR hydromorphone administered over 24 hours in healthy volunteers
U. Richarz, Joris J. Vandenbossche, K. Moore
20111 citations Open access
Semantic Scholar
Steady-state pharmacokinetic profile of OROS hydromorphone extended release and hydromorphone immediate release
K. Moore, D. St Fleur, N. C. Marricco, T. Ariyawansa +4 more
20101 citations Open access
Semantic Scholar
Peripheral Artery Disease, the Factor Xa Inhibitor Rivaroxaban, and the Role of the Podiatrist
J. Evans, Nicholas C. Claussen, C. Leslie, K. Moore
20210 citations
Semantic Scholar
Abstract 23: Patient Level Prediction Models Developed With Large Observational Databases Outperformed Existing Clinical Prediction Scores For Stratifying Bleeding Risk In Patients With Atrial Fibrillation
C. Blacketer, J. Reps, Lu Wang, Qingqing Li +8 more
2019Circulation. Cardiovascular Quality and Outcomes0 citations
Semantic Scholar
Rivaroxaban and its Use in the Elderly, What Do We Know?
K. Moore
20180 citations Open access
Semantic Scholar
Anticoagulation and Cancer-Associated Venous Thromboembolism inAmbulatory Patients-Are Factor Xa Inhibitors the Next Logical Step?
K. Moore, Maria Langas
20180 citations
Semantic Scholar
Clarification—safety and efficacy of apixaban versus warfarin in patients with end‐stage renal disease: Meta‐analysis
K. Moore
2018Pacing and clinical electrophysiology : PACE0 citations Open access
Semantic Scholar
Clarification of the use of rivaroxaban in renal patients
K. Moore
2018British Journal of Haematology0 citations Open access
Semantic Scholar
American Geriatrics Society Beers Criteria and Anticoagulant Use in Older Adults With Renal Impairment
J. Foody, K. Moore
2017Kidney International Reports0 citations Open access
Semantic Scholar
Effects of Renal Impairment and Chronic Hemodialysis on thePharmacokinetics, Pharmacodynamics and Safety of Rivaroxaban
Maria Langas, K. Moore
20170 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

V. Ashton×12
Invite
V. Ashton — researcher profile on SciRah
J. Ariyawansa×8
Invite
J. Ariyawansa — researcher profile on SciRah
J. Natarajan×7
Invite
J. Natarajan — researcher profile on SciRah
U. Richarz×5
Invite
U. Richarz — researcher profile on SciRah

×5

Invite

J. Berger — researcher profile on SciRah

F. Laliberté×5

Invite

F. Laliberté — researcher profile on SciRah

Invite

A. Kharat — researcher profile on SciRah

Invite

D. Lejeune — researcher profile on SciRah

Invite

Y. Jung — researcher profile on SciRah

Invite

P. Lefebvre — researcher profile on SciRah

Invite

L. Haskell — researcher profile on SciRah

Invite

M. Weir — researcher profile on SciRah